Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis
- PMID: 22431799
- PMCID: PMC3493180
- DOI: 10.1093/cid/cis299
Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis
Abstract
Background: Escherichia coli O157:H7 is the leading cause of hemolytic uremic syndrome (HUS). Risk factors for development of this complication warrant identification.
Methods: We enrolled children infected with E. coli O157:H7 within 1 week of the onset of diarrhea in this prospective cohort study. The study was conducted in 5 states over 9.5 years . The primary and secondary outcomes were HUS (hematocrit <30% with smear evidence of hemolysis, platelet count <150 × 10(3)/µL, and serum creatinine concentration > upper limit of normal for age) and oligoanuric HUS. Univariate and multivariable and ordinal multinomial regression analyses were used to test associations between factors apparent during the first week of illness and outcomes.
Results: Of the 259 children analyzed, 36 (14%) developed HUS. Univariate analysis demonstrated that children who received antibiotics during the diarrhea phase more frequently developed HUS than those who did not (36% vs 12%; P = .001). The higher rate of HUS was observed across all antibiotic classes used. In multivariable analysis, a higher leukocyte count (adjusted odds ratios [aOR] 1.10; 95% CI, 1.03-1.19), vomiting (aOR 3.05; 95% CI, 1.23-7.56), and exposure to antibiotics (aOR 3.62; 95% CI, 1.23-10.6) during the first week of onset of illness were each independently associated with development of HUS. Multinomial ordinal logistic regression confirmed that initial leukocyte count and antibiotic use were independently associated with HUS and, additionally, these variables were each associated with the development of oligoanuric HUS.
Conclusions: Antibiotic use during E. coli O157:H7 infections is associated with a higher rate of subsequent HUS and should be avoided.
Similar articles
-
Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.Pediatrics. 2005 Jun;115(6):e673-80. doi: 10.1542/peds.2004-2236. Pediatrics. 2005. PMID: 15930195
-
Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections.Pediatrics. 1997 Jul;100(1):E12. doi: 10.1542/peds.100.1.e12. Pediatrics. 1997. PMID: 9200386
-
Strength of the association between antibiotic use and hemolytic uremic syndrome following Escherichia coli O157:H7 infection varies with case definition.Int J Med Microbiol. 2018 Oct;308(7):921-926. doi: 10.1016/j.ijmm.2018.06.009. Epub 2018 Jun 26. Int J Med Microbiol. 2018. PMID: 30257808 Free PMC article.
-
Relationship between Escherichia coli O157:H7 and diabetes mellitus.Kidney Int Suppl. 2009 Feb;(112):S44-6. doi: 10.1038/ki.2008.619. Kidney Int Suppl. 2009. PMID: 19180134 Review.
-
Interventions for preventing diarrhea-associated hemolytic uremic syndrome: systematic review.BMC Public Health. 2013 Sep 3;13:799. doi: 10.1186/1471-2458-13-799. BMC Public Health. 2013. PMID: 24007265 Free PMC article. Review.
Cited by
-
An anti-Shiga toxin VHH nanobody multimer protects mice against fatal toxicosis when administered intramuscularly as repRNA.Infect Immun. 2024 Nov 12;92(11):e0023924. doi: 10.1128/iai.00239-24. Epub 2024 Oct 11. Infect Immun. 2024. PMID: 39392311 Free PMC article.
-
Synthetic phage-based approach for sensitive and specific detection of Escherichia coli O157.Commun Biol. 2024 May 6;7(1):535. doi: 10.1038/s42003-024-06247-w. Commun Biol. 2024. PMID: 38710842 Free PMC article.
-
Haemolytic uraemic syndrome in children England, Wales, Northern Ireland, and Ireland: A prospective cohort study.Epidemiol Infect. 2023 Sep 1;151:e160. doi: 10.1017/S0950268823001413. Epidemiol Infect. 2023. PMID: 37655611 Free PMC article.
-
Antibacterial MccM as the Major Microcin in Escherichia coli Nissle 1917 against Pathogenic Enterobacteria.Int J Mol Sci. 2023 Jul 20;24(14):11688. doi: 10.3390/ijms241411688. Int J Mol Sci. 2023. PMID: 37511446 Free PMC article.
-
Hyperhydration to Improve Kidney Outcomes in Children with Shiga Toxin-Producing E. coli Infection: a multinational embedded cluster crossover randomized trial (the HIKO STEC trial).Trials. 2023 May 27;24(1):359. doi: 10.1186/s13063-023-07379-w. Trials. 2023. PMID: 37245030 Free PMC article. Clinical Trial.
References
-
- Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005;365:1073–86. - PubMed
-
- Chandler WL, Jelacic S, Boster DR, et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med. 2002;346:23–32. - PubMed
-
- Carter AO, Borczyk AA, Carlson JA, et al. A severe outbreak of Escherichia coli O157:H7–associated hemorrhagic colitis in a nursing home. N Engl J Med. 1987;317:1496–500. - PubMed
-
- Grif K, Dierich MP, Karch H, Allerberger F. Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur J Clin Microbiol Infect Dis. 1998;17:761–6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
